Danish allergy vaccine firm ALK-Abello A/S said it expects to add DKK50 million to DKK52 million (US$9.1 million to US$9.5 million) to its earnings and its revenues in the coming year, because of a revision to Germany’s drug pricing regime that took effect on Jan. 1.